» Articles » PMID: 28231894

[New Therapeutic Developments in Cystic Fibrosis]

Overview
Journal Arch Pediatr
Publisher Elsevier
Specialty Pediatrics
Date 2017 Feb 25
PMID 28231894
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Since the discovery of chloride secretion by the Cystic Fibrosis Transport regulator CFTR in 1983, and CFTR gene in 1989, knowledge about CFTR synthesis, maturation, intracellular transfer and function has dramatically expanded. These discoveries have led to the distribution of CF mutations into 6 classes with different pathophysiological mechanisms. In this article we will explore the state of art on CFTR synthesis and its chloride secretion function. We will then explore the consequences of the 6 classes of mutations on CFTR protein function and we will describe the new therapeutic developments aiming at correcting these defects.

Citing Articles

Editorial: New insights into caring for pediatric patients with cystic fibrosis.

Bui S, Delhaes L, Dournes G, Reix P, Fayon M Front Pediatr. 2023; 11:1243496.

PMID: 37635799 PMC: 10450029. DOI: 10.3389/fped.2023.1243496.


Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis.

Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F Front Pediatr. 2021; 9:744705.

PMID: 34869102 PMC: 8634876. DOI: 10.3389/fped.2021.744705.